Figure 1.

Comparison of neutralization titers of variant spike protein pseudotyped viruses by convalescent sera, antibodies elicited by BNT162b2, mRNA-1273, Ad26.COV2.S. (A) Neutralization of variant spike protein pseudotyped viruses by convalescent serum (n = 8) (left). Neutralizing titers of serum samples from BNT162b2 vaccinated individuals (n = 15) (middle). Neutralizing titers of serum samples from mRNA-1273 vaccinated donors (n = 6) (right). The serum was collected at early time point (7 days after second immunization). Serum samples from Ad26.COV2.S vaccinated donors were not available. The neutralization IC₅₀ from individual donors is shown. Significance is based on two-sided t-test. Units on the Y axis of the graph for convalescent serum samples has been adjusted to allow for visualization of the data. (B) Comparison of neutralization of variants by convalescent serum (n = 8, the same donors in A), BNT162b2 vaccinated individuals (n = 9), mRNA-1273 vaccinated donors (n = 8), Ad26.COV2.S vaccinated donors (n = 10), sera from vaccinated individuals were collected at later time points [Day 52-110 (mean 90), Day 44-105 (mean 80), Day 57-115 (mean 82 days) after last immunization of each vaccine, see the Supplementary Table 2]. Each line shows individual donors. (C) Comparison of neutralization potency of each vaccine by different SARS-CoV-2 variants. The neutralization IC₅₀ from individual donors vaccinated by BNT162b2 (yellow), mRNA-1273 (pink), Ad26.COV2.S (black) is shown. Significance is based on two-sided t-test. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).